Published in Biochemistry on October 26, 1999
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
The kinetochore-bound Ska1 complex tracks depolymerizing microtubules and binds to curved protofilaments. Dev Cell (2012) 1.54
Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep (2008) 1.32
Interactions of halichondrin B and eribulin with tubulin. J Chem Inf Model (2011) 1.19
Antitumor peptides from marine organisms. Mar Drugs (2011) 0.99
A new model for binding of kinesin 13 to curved microtubule protofilaments. J Cell Biol (2009) 0.98
The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform (2007) 0.98
Visualisation of a kinesin-13 motor on microtubule end mimics. J Mol Biol (2008) 0.93
HIV-1 rev depolymerizes microtubules to form stable bilayered rings. J Cell Biol (2000) 0.88
Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor. Invest New Drugs (2011) 0.78
Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation. Mol Divers (2014) 0.77
Bombesin marine toxin conjugates inhibit the growth of lung cancer cells. Life Sci (2008) 0.76
Ethyl acetate extract from marine sponge Hyattella cribriformis exhibit potent anticancer activity by promoting tubulin polymerization as evidenced mitotic arrest and induction of apoptosis. Pharmacogn Mag (2015) 0.75
Complementary isonitrile-based multicomponent reactions for the synthesis of diversified cytotoxic hemiasterlin analogues. Org Biomol Chem (2015) 0.75
Evidence based medicine: what it is and what it isn't. BMJ (1996) 66.70
Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine. Lancet (1995) 24.14
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med (1991) 18.33
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
Bias in analytic research. J Chronic Dis (1979) 16.40
Requirement of an Escherichia coli 50 S ribosomal protein component for effective interaction of the ribosome with T and G factors and with guanosine triphosphate. J Biol Chem (1972) 14.68
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
The number needed to treat: a clinically useful measure of treatment effect. BMJ (1995) 13.89
An assessment of clinically useful measures of the consequences of treatment. N Engl J Med (1988) 13.02
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (1998) 11.27
Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med (1978) 9.29
Controversy in the detection of disease. Lancet (1975) 7.85
How to keep up with the medical literature: V. Access by personal computer to the medical literature. Ann Intern Med (1986) 7.36
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet (1975) 7.22
Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. JAMA (1993) 6.83
A utility maximization model for evaluation of health care programs. Health Serv Res (1972) 6.67
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem (1997) 5.51
Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA (1995) 5.28
Problems in the handling of clinical and research evidence by medical practitioners. Arch Intern Med (1983) 5.16
A randomized trial of continuing medical education. N Engl J Med (1982) 4.95
Improvement of medication compliance in uncontrolled hypertension. Lancet (1976) 4.84
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
The utility of different health states as perceived by the general public. J Chronic Dis (1978) 3.65
An empirical demonstration of Berkson's bias. J Chronic Dis (1978) 3.48
Can simple clinical measurements detect patient noncompliance? Hypertension (1981) 3.29
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation (1996) 3.23
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1986) 3.16
p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol (2000) 3.05
Does a mailed continuing education program improve physician performance? Results of a randomized trial in antihypertensive care. JAMA (1986) 3.04
Choosing the best research design for each question. BMJ (1998) 3.03
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis (1985) 2.96
How to keep up with the medical literature: I. Why try to keep up and how to get started. Ann Intern Med (1986) 2.94
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia (1989) 2.90
Quality-of-care appraisal in primary care: a quantitative method. Ann Intern Med (1975) 2.87
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1992) 2.81
Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol (1998) 2.81
Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer (2000) 2.73
Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol (1995) 2.73
The development and application of indices of health: general methods and a summary of results. Am J Public Health (1977) 2.53
Clinical recommendations using levels of evidence for antithrombotic agents. Chest (1995) 2.52
Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem (1997) 2.41
Using research findings in clinical practice. BMJ (1998) 2.40
The rational clinical examination. Does this patient have splenomegaly? JAMA (1993) 2.38
The rational clinical examination. Does this patient have a clinically important carotid bruit? JAMA (1993) 2.38
Hypertension in a family practice. Can Med Assoc J (1977) 2.36
Synthesis of epothilones A and B in solid and solution phase. Nature (1997) 2.35
Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry (1989) 2.34
Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst (2000) 2.33
Rules of evidence and clinical recommendations for the management of patients. Can J Cardiol (1993) 2.11
When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med (1985) 2.11
Transferring evidence from research into practice: 1. The role of clinical care research evidence in clinical decisions. ACP J Club (1996) 2.10
Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry (1984) 2.04
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Guidelines for managing raised blood pressure. BMJ (1996) 2.03
Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) J Med Chem (1995) 1.98
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res (1997) 1.97
Cardiovascular diseases. Lancet (1974) 1.85
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem (1991) 1.84
Fenoterol and fatal asthma. Lancet (1990) 1.77
Labelling in hypertension: a review of the behavioural and psychological consequences. J Chronic Dis (1984) 1.75
How to keep up with the medical literature: IV. Using the literature to solve clinical problems. Ann Intern Med (1986) 1.75
Cochrane Collaboration. BMJ (1994) 1.74
Educational package on hypertension for primary care physicians. Can Med Assoc J (1984) 1.73
Tubulin subunit carboxyl termini determine polymerization efficiency. J Biol Chem (1985) 1.73
Odds ratios should be avoided when events are common. BMJ (1998) 1.71
Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. J Med Chem (1998) 1.71
Clinical diagnosis and the clinical laboratory. Clin Invest Med (1978) 1.67
Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. N Engl J Med (1977) 1.66
Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod (1987) 1.64
Understanding clinical trials. BMJ (1994) 1.59
How to keep up with the medical literature: II. Deciding which journals to read regularly. Ann Intern Med (1986) 1.57
Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol (1988) 1.54
Tubulin, hybrid dimers, and tubulin S. Stepwise charge reduction and polymerization. J Biol Chem (1985) 1.54
On the need for evidence-based medicine. Health Econ (1996) 1.53
Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry (1996) 1.52
Evaluation of neonatal-intensive-care program. N Engl J Med (1981) 1.52
Cancer risk in ulcerative colitis: scientific requirements for the study of prognosis. Gastroenterology (1980) 1.50
The fall of "clinical research" and the rise of "clinical-practice research". Clin Invest Med (2000) 1.50
Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res (1992) 1.49
The science of the art of the clinical examination. JAMA (1992) 1.48
Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg Med Chem Lett (2001) 1.48
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem (1990) 1.47
Self-recording of blood pressure in the management of hypertension. Can Med Assoc J (1978) 1.46
The usefulness of laboratory tests in health-screening programs. Clin Chem (1973) 1.45
Applying the results of trials and systematic reviews to individual patients. ACP J Club (1998) 1.45
Concordance for coronary risk factors among spouses. Circulation (1975) 1.44
Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J Cereb Blood Flow Metab (1997) 1.44
2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A (1994) 1.43
Non-use and misuse of measles vaccine. Can Fam Physician (1973) 1.40